New York State Teachers Retirement System decreased its holdings in Oracle Corporation (NYSE:ORCL – Free Report) by 0.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,358,287 shares of the enterprise software provider’s stock after selling 5,890 shares during the period. Oracle comprises approximately 0.6% of New York State Teachers Retirement System’s investment portfolio, making the stock its 21st biggest holding. New York State Teachers Retirement System’s holdings in Oracle were worth $296,962,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Reyes Financial Architecture Inc. grew its holdings in shares of Oracle by 7.2% in the second quarter. Reyes Financial Architecture Inc. now owns 643 shares of the enterprise software provider’s stock valued at $141,000 after purchasing an additional 43 shares in the last quarter. Creative Capital Management Investments LLC grew its holdings in shares of Oracle by 5.7% in the second quarter. Creative Capital Management Investments LLC now owns 798 shares of the enterprise software provider’s stock valued at $174,000 after purchasing an additional 43 shares in the last quarter. MFA Wealth Services grew its holdings in shares of Oracle by 1.0% in the second quarter. MFA Wealth Services now owns 4,563 shares of the enterprise software provider’s stock valued at $998,000 after purchasing an additional 43 shares in the last quarter. Davis Investment Partners LLC grew its holdings in shares of Oracle by 0.7% in the second quarter. Davis Investment Partners LLC now owns 6,930 shares of the enterprise software provider’s stock valued at $1,517,000 after purchasing an additional 46 shares in the last quarter. Finally, Acropolis Investment Management LLC grew its holdings in shares of Oracle by 2.6% in the second quarter. Acropolis Investment Management LLC now owns 1,850 shares of the enterprise software provider’s stock valued at $404,000 after purchasing an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 42.44% of the company’s stock.
Oracle Stock Up 1.4%
ORCL stock opened at $303.30 on Thursday. The company has a market cap of $864.64 billion, a P/E ratio of 70.21, a P/E/G ratio of 3.22 and a beta of 1.53. Oracle Corporation has a 52 week low of $118.86 and a 52 week high of $345.72. The company’s 50-day moving average price is $269.61 and its 200 day moving average price is $213.14. The company has a current ratio of 0.62, a quick ratio of 0.62 and a debt-to-equity ratio of 3.33.
Oracle Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 23rd. Shareholders of record on Thursday, October 9th will be given a dividend of $0.50 per share. The ex-dividend date is Thursday, October 9th. This represents a $2.00 dividend on an annualized basis and a yield of 0.7%. Oracle’s payout ratio is presently 46.30%.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on ORCL. Melius Research lifted their price objective on shares of Oracle from $270.00 to $370.00 and gave the company a “buy” rating in a report on Wednesday, September 10th. BMO Capital Markets set a $355.00 price target on shares of Oracle and gave the stock an “outperform” rating in a report on Monday. JPMorgan Chase & Co. boosted their price target on shares of Oracle from $185.00 to $210.00 and gave the stock a “neutral” rating in a report on Monday, September 8th. UBS Group set a $364.00 price target on shares of Oracle in a report on Friday, September 26th. Finally, BNP Paribas set a $377.00 price target on shares of Oracle in a report on Wednesday, September 10th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-seven have given a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $307.00.
Read Our Latest Stock Report on Oracle
Insider Activity at Oracle
In other Oracle news, Director Naomi O. Seligman sold 2,222 shares of Oracle stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $288.91, for a total transaction of $641,958.02. Following the completion of the transaction, the director owned 29,225 shares in the company, valued at approximately $8,443,394.75. The trade was a 7.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Clayton M. Magouyrk sold 21,241 shares of Oracle stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $297.11, for a total transaction of $6,310,913.51. Following the transaction, the insider owned 78,000 shares of the company’s stock, valued at approximately $23,174,580. The trade was a 21.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,769 shares of company stock valued at $36,428,967 in the last quarter. 40.90% of the stock is owned by corporate insiders.
About Oracle
Oracle Corporation offers products and services that address enterprise information technology environments worldwide. Its Oracle cloud software as a service offering include various cloud software applications, including Oracle Fusion cloud enterprise resource planning (ERP), Oracle Fusion cloud enterprise performance management, Oracle Fusion cloud supply chain and manufacturing management, Oracle Fusion cloud human capital management, Oracle Cerner healthcare, Oracle Advertising, and NetSuite applications suite, as well as Oracle Fusion Sales, Service, and Marketing.
Read More
- Five stocks we like better than Oracle
- The How And Why of Investing in Oil Stocks
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- 3 Tickers Leading a Meme Stock Revival
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Oracle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oracle and related companies with MarketBeat.com's FREE daily email newsletter.